|Pretty sucky, overall.|
Perhaps JNJ doesn't mention the potential of their molecules for a reason? In the history of biotech, there's never been a lousier partner than JNJ. For all we know, they've sand bagged Centocor.
The upside? Scratch one more management team that didn't have a concept of the breadth of the job that needed doing. They did the job, as they conceived of it, pretty well. But that's not enough.
Silly decision to fill the pipe with a molecule that needed so much preclinical, and a molecule that didn't fit the infrastructure, at that.